Literature DB >> 28581460

MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD.

A-M Boekstegers1, F Blaeschke1, I Schmid1, V Wiebking1, S Immler1, F Hoffmann1, K Bochmann2, S Müller3, T G P Grünewald4, J Feucht5, T Feuchtinger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28581460     DOI： 10.1038/bmt.2017.107

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

1.  Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.

Authors:  G Escherich; M A Horstmann; M Zimmermann; G E Janka-Schaub
Journal:  Leukemia       Date:  2009-12-17       Impact factor: 11.528

2.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

3.  Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.

Authors:  A K Singh; L F Porrata; O Aljitawi; T Lin; L Shune; S Ganguly; J P McGuirk; S Abhyankar
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

4.  Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Authors:  L Angenendt; C Schliemann; M Lutz; E Rebber; A B Schulze; M Weckesser; L Stegger; M Schäfers; C Groth; T Kessler; G Lenz; M Stelljes; W E Berdel
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

Review 5.  Immune checkpoint blockade: Releasing the brake towards hematological malignancies.

Authors:  Yi Xia; L Jeffrey Medeiros; Ken H Young
Journal:  Blood Rev       Date:  2015-11-25       Impact factor: 8.250

6.  Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.

Authors:  Martin Schrappe; Maria Grazia Valsecchi; Claus R Bartram; André Schrauder; Renate Panzer-Grümayer; Anja Möricke; Rosanna Parasole; Martin Zimmermann; Michael Dworzak; Barbara Buldini; Alfred Reiter; Giuseppe Basso; Thomas Klingebiel; Chiara Messina; Richard Ratei; Giovanni Cazzaniga; Rolf Koehler; Franco Locatelli; Beat W Schäfer; Maurizio Aricò; Karl Welte; Jacques J M van Dongen; Helmut Gadner; Andrea Biondi; Valentino Conter
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

7.  Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

Authors:  Raanan Berger; Rinat Rotem-Yehudar; Gideon Slama; Shimon Landes; Abraham Kneller; Merav Leiba; Maya Koren-Michowitz; Avichai Shimoni; Arnon Nagler
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

8.  CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.

Authors:  Asad Bashey; Bridget Medina; Sue Corringham; Mildred Pasek; Ewa Carrier; Linda Vrooman; Israel Lowy; Scott R Solomon; Lawrence E Morris; H Kent Holland; James R Mason; Edwin P Alyea; Robert J Soiffer; Edward D Ball
Journal:  Blood       Date:  2008-10-30       Impact factor: 22.113

9.  T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.

Authors:  Judith Feucht; Simone Kayser; David Gorodezki; Mohamad Hamieh; Michaela Döring; Franziska Blaeschke; Patrick Schlegel; Hans Bösmüller; Leticia Quintanilla-Fend; Martin Ebinger; Peter Lang; Rupert Handgretinger; Tobias Feuchtinger
Journal:  Oncotarget       Date:  2016-11-22

10.  Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective.

Authors:  Jose Caetano Villasboas; Stephen M Ansell; Thomas E Witzig
Journal:  Oncotarget       Date:  2016-03-15
View more
  5 in total

Review 1.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.

Authors:  Awais Ijaz; Ali Younas Khan; Saad Ullah Malik; Warda Faridi; Muhammad Asad Fraz; Muhammad Usman; Muhammad Junaid Tariq; Seren Durer; Ceren Durer; Atlantis Russ; Nadia Nunes Cavalcante Parr; Zeeshan Baig; Fnu Sagar; Zeeshan Ali; Ali McBride; Faiz Anwer
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-06       Impact factor: 5.742

Review 2.  Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.

Authors:  Qingxiao Song; Ubaydah Nasri; Ryotaro Nakamura; Paul J Martin; Defu Zeng
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

Review 3.  The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Natalie Köhler; Dietrich Alexander Ruess; Rebecca Kesselring; Robert Zeiser
Journal:  Front Immunol       Date:  2021-03-05       Impact factor: 7.561

4.  Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

Authors:  Sun Yao; Chen Jianlin; Qiao Zhuoqing; Li Yuhang; Hu Jiangwei; Hu Guoliang; Ning Hongmei; Zhang Bin; Hu Liangding
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

5.  Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus.

Authors:  Guillermo E Almodovar Cruz; Genevieve Kaunitz; Julie E Stein; Inbal Sander; Travis Hollmann; Tricia R Cottrell; Janis M Taube; Joel C Sunshine
Journal:  J Cutan Pathol       Date:  2022-05-16       Impact factor: 1.458
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.